A study to compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 with US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.

2025-523115-11-00 · tracked via the Priya Life Science EU tracker

Sponsor

Chong Kun Dang Pharmaceutical Corp.

Sponsor type

Pharmaceutical company

Therapeutic area

Immune System Diseases

Decision date

09/01/2026

Enrollment target

335

Sites

Germany

Condition studied

Phase I study in healthy participants. Intended indication: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease

Eligibility

Age group

18-64 years

Sex

Female, Male

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523115-11-00 on CTIS ↗ ← All trials in the EU